Physician-reported Clinical Unmet Needs, Burden and Treatment Patterns of Paediatric Psoriasis Patients: A US and EU Real-world Evidence Study

Abstract

This study is a retrospective analysis using data collected from the Adelphi Paediatric Psoriasis Disease-Specific Programme cross-sectional survey. Despite being treated for their psoriasis, a substantial proportion of paediatric patients presented with moderate (18.3%) or severe (1.3%) disease at sampling; 42.9% and 92.0% had a body surface area (BSA) of >10%, and 38.8% and 100.0% had a Psoriasis Area Severity Index (PASI) score >10, respectively. Overall, 69.9% of patients had only ever been treated with a topical therapy for their psoriasis. For patients with moderate or severe disease at sampling, 16.3% and 14.4% were currently receiving conventional systemics or biologic therapy, respectively. There is a clinical unmet need in this paediatric population; a considerable percentage of patients still experienced moderate or severe disease and persistent psoriasis symptoms, with numerous body areas affected. A significant proportion of patients were undertreated, which may explain the high burden of disease observed.

Patient-reported Outcomes and Burden of Disease in Paediatric Patients with Psoriasis: Real-world Data from EU5 and US

“…Methods of this retrospective analysis of a cross-sectional survey have been reported previously ( 10 ). In brief, dermatologists, general practitioners or primary care practitioners (GP/PCP), and paediatricians actively managing paediatric patients with PsO were included.…”

“…In brief, dermatologists, general practitioners or primary care practitioners (GP/PCP), and paediatricians actively managing paediatric patients with PsO were included. All physicians completed a patient record form (PRF) for the subsequent 10 paediatric patients with PsO attending their practice (PRF details published previously ( 10 )). Each patient was invited by their physician to complete a voluntary self-completion questionnaire.…”

“…Furthermore, due to the visibility of psoriatic plaques, paediatric patients with PsO experience social discomfort, bullying and stigma ( 6 – 9 ). Previously we have described physician-reported clinical unmet needs and treatment patterns in a real-world population of >2,000 paediatric patients with PsO ( 10 ).…”

Psoriasis in children and adolescents

“…Die Realität sieht jedoch anders aus. Einer Querschnittumfrage bei über 300 US-amerikanischen und europäischen Ärzten (58 % Dermatologen, 22 % Allgemeinmediziner, 20 % Pädiater) zufolge hatten in dieser Altersgruppe nur 15,3 % der Patienten mit moderater und 17,2 % der Patienten mit schwerer Psoriasis jemals eine Systemtherapie erhalten [ 23 ]. Mithin besteht noch immer ein erheblicher ungedeckter Bedarf an ausreichender Behandlung.…”

Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability

“…Therapy, mainly due to the necessity of treating children off-label, may be more challenging. 6 , 26 Treatment for psoriasis consists of a range of topical medications, phototherapy, non-biologic and biologic systemic therapies. Topical treatment of PsO is mostly based on corticosteroids, calcineurin inhibitors, and vitamin D3 analogues.…”